Hanyi Fang1,2, Samantha Rossano3, Xingxing Wang4, Nabeel Nabulsi3, Brian Kelley5, Krista Fowles3, Jim Ropchan3, Stephen M Strittmatter4, Richard E Carson3, Yiyun Huang6. 1. PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA. fanghanyi@hust.edu.cn. 2. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. fanghanyi@hust.edu.cn. 3. PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA. 4. Cellular Neuroscience, Neurodegeneration, and Repair Program, and Departments of Neurology and Neurobiology, Yale School of Medicine, New Haven, CT, USA. 5. Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA. 6. PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA. henry.huang@yale.edu.
Abstract
PURPOSE: The descending raphespinal serotonin (5-HT) system contributes to neural activities required for locomotion. The presynaptic serotonin transporter (SERT) is a marker of 5-HT innervation. In this study, we explored the use of PET imaging with the SERT radioligand [11C]AFM as a biomarker of 5-HT axon damage after spinal cord injury (SCI) in a rodent model and its translation to imaging SCI in humans. PROCEDURES: PET imaging with [11C]AFM was performed in healthy rats under baseline and citalopram blocking conditions and a mid-thoracic transection rat model of SCI. The lumbar-to-cervical activity (L/C) ratio was calculated for the healthy and SCI animals to assess SERT binding decrease after SCI. Finally, translation of [11C]AFM PET was attempted to explore its potential to image SCI in humans. RESULTS: Intense uptake in the brain and intact spinal cord was observed at 30-60 min post-injection of [11C]AFM in healthy rats. About 65% of [11C]AFM uptake in the spinal cord was blocked by citalopram. In the SCI rat model, the cervical uptake of [11C]AFM was similar to that in healthy rats, but the lumbar uptake was dramatically reduced, resulting in about half the L/C ratio in SCI rats compared to healthy rats. In contrast, [11C]AFM uptake in the human spinal cord showed no obvious decrease after treatment with citalopram. In the human subjects with SCI, decreases in [11C]AFM uptake were also not obvious in the section of spinal cord caudal to the injury point. CONCLUSION: [11C]AFM PET imaging of SERT provides a useful preclinical method to non-invasively visualize the rodent spinal cord and detect SERT changes in SCI rodent models. However, there appears to be little detectable specific binding signal for [11C]AFM in the human spinal cord. An SERT tracer with higher affinity and lower non-specific binding signal is needed to image the spinal cord in humans and to assess the axonal status in SCI patients.
PURPOSE: The descending raphespinal serotonin (5-HT) system contributes to neural activities required for locomotion. The presynaptic serotonin transporter (SERT) is a marker of 5-HT innervation. In this study, we explored the use of PET imaging with the SERT radioligand [11C]AFM as a biomarker of 5-HT axon damage after spinal cord injury (SCI) in a rodent model and its translation to imaging SCI in humans. PROCEDURES: PET imaging with [11C]AFM was performed in healthy rats under baseline and citalopram blocking conditions and a mid-thoracic transection rat model of SCI. The lumbar-to-cervical activity (L/C) ratio was calculated for the healthy and SCI animals to assess SERT binding decrease after SCI. Finally, translation of [11C]AFM PET was attempted to explore its potential to image SCI in humans. RESULTS: Intense uptake in the brain and intact spinal cord was observed at 30-60 min post-injection of [11C]AFM in healthy rats. About 65% of [11C]AFM uptake in the spinal cord was blocked by citalopram. In the SCI rat model, the cervical uptake of [11C]AFM was similar to that in healthy rats, but the lumbar uptake was dramatically reduced, resulting in about half the L/C ratio in SCI rats compared to healthy rats. In contrast, [11C]AFM uptake in the human spinal cord showed no obvious decrease after treatment with citalopram. In the human subjects with SCI, decreases in [11C]AFM uptake were also not obvious in the section of spinal cord caudal to the injury point. CONCLUSION: [11C]AFM PET imaging of SERT provides a useful preclinical method to non-invasively visualize the rodent spinal cord and detect SERT changes in SCI rodent models. However, there appears to be little detectable specific binding signal for [11C]AFM in the human spinal cord. An SERT tracer with higher affinity and lower non-specific binding signal is needed to image the spinal cord in humans and to assess the axonal status in SCI patients.
Authors: Christie Engesser-Cesar; Ronaldo M Ichiyama; Amber L Nefas; Mary Ann Hill; V Reggie Edgerton; Carl W Cotman; Aileen J Anderson Journal: Eur J Neurosci Date: 2007-04 Impact factor: 3.386
Authors: Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn Journal: J Cereb Blood Flow Metab Date: 2009-09-09 Impact factor: 6.200
Authors: James W Murrough; Yiyun Huang; Jian Hu; Shannan Henry; Wendol Williams; Jean-Dominique Gallezot; Christopher R Bailey; John H Krystal; Richard E Carson; Alexander Neumeister Journal: Biol Psychiatry Date: 2011-12-01 Impact factor: 13.382
Authors: Ramona E von Leden; Kasey E Moritz; Sara Bermudez; Shalini Jaiswal; Colin M Wilson; Bernard J Dardzinski; Kimberly R Byrnes Journal: Neurosci Lett Date: 2018-10-06 Impact factor: 3.046
Authors: J L Tremoleda; O Thau-Zuchman; M Davies; J Foster; I Khan; K C Vadivelu; P K Yip; J Sosabowski; W Trigg; A T Michael-Titus Journal: Eur J Nucl Med Mol Imaging Date: 2016-05-07 Impact factor: 9.236